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INTRODUCTION 
This review discusses the patient’s perspective and biological basis for sex and gender differences in 
functional gastrointestinal (GI) disorders (FGIDs).  Attention is given to the lived experience of irritable 
bowel syndrome (IBS) as well as the importance of patient interaction with the health care provider. In 
addition, the review highlights the current literature related to gender- and sex-based differences in 
visceral and somatic sensitivity, pain, motility, and the overlap of FGIDs, in particular IBS, with other 
chronic conditions.    
 
THE PATIENTS PERSPECTIVE 
The Patient Experience of FGIDs  
“IBS is very frustrating: it dominates life style and daily activities mostly through its unpredictability. 
You must always plan for the ‘what if’ ‘what if I eat more’ ‘what if toilet facilities are not available’  
‘what if I cannot break away’.  It leaves you feeling  ‘dirty or unclean’ and inhibits social mixing and 
sexual activity.  IBS is frustrating.  And that’s the bottom line…….”  IBS study participant. 
  
For patients with chronic symptoms the psychological and social ramifications of their illness are often 
more important than the physical impairment . Three overriding themes seem to dominate the experience 
of living with moderate to severe FGID: 1) a sense of frustration, 2) a sense of isolation and 3) search for 
niche in the health/sick role continuum/dissatisfaction with the medical system.1-4  The effects of IBS on 
quality of life (QoL) are often underestimated. Patients with mild to moderate disease severity report that 
IBS restricts daily activities on average 73 days per year (20%); resulting in loss of work (13% of 
patients).5 
 There is often a disconnect between patients’ and physicians’ views of the IBS experience, 
regarding perceptions of etiology, severity, treatment approaches, and efficacy.6-8  When 1,014 patients 
and 508 physicians used identical scales to rate IBS-related pain and discomfort, responses showed that 
physicians rated discomfort as significantly less severe than patients.9  Conversely, 35% of more than a 
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1000 IBS patients in an international survey, reported their symptoms as ‘severe’. In the same survey, to 
receive a treatment that would make them symptom free, patients would give up 25% of their remaining 
life (average 15 yrs) and 14% would risk a 1/1000 chance of death.5  Many patients are reluctant to accept 
the “functional” diagnosis and many misconceptions, for example that anxiety, depression, and diet cause 
IBS, and fear that IBS leads to cancer.7, 8 Such misconceptions are likely affecting clinical outcomes and 
health care utilization. 
 
The Patient-Health Care Provider Encounter 
“The biggest problem is that no one (in the medical field) treats the whole person.  I feel more like I’m 
going to a drug dealer than someone that looks at the problem in its totality.  As a result I have turned my 
attention to helping myself, and have had some degree of success. I wish doctors would listen to patients 
more when we talk about the symptoms and how they affect our daily lives” IBS study participant. 
 
 Only a small proportion (≈25%) of IBS sufferers consult physicians.10  However, those who do, 
have high health care utilization.11  The nature of patient-physician relationship is complex. Factors 
within and outside the health care system are constantly molding patient and physician behavior. Patients 
feel frustrated with unsatisfactory explanation of FGIDs which may be experienced as a denial of the 
legitimacy of their symptoms and perceive lack of empathy.2  Conversely, physician frustration and 
dissatisfaction related to treating patients with FGIDs stem from a lack of understanding of the disease, 
limited treatment options, limited training in communication skills, increased workload, and the 
perception of personality characteristics of patients with IBS with psychiatric comorbidities.12  
Gastroenterologists perceive that patients with IBS require longer visits despite not being as sick as 
patients with other disorders that they manage9 and can show gender bias.13 Negative attitudes toward 
patients with IBS may form a barrier to objective patient assessment and effective physician-patient 
relationship building, and ultimately negatively  impact clinical outcome.14  Effective communication 
skills can be learned and practiced and, importantly, do not increase the encounter time. Rather, effective 
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communication skills make the process of assessment and diagnosis more efficient, improve clinical 
outcomes and increase physician job satisfaction.15-17 
 IBS can be challenging for both the physician and the patient. Patients must learn to self-manage 
a condition that can have a profound impact on everyday  life. Health care providers can help by eliciting 
and addressing patient concerns, by offering a positive diagnosis and clear, understandable, and 
legitimizing explanations of the disorder, show empathy and enter into a meaningful partnership that 
helps individuals replace feelings of helplessness with means of empowerment. 
 
GENDER 
Sex refers to the biological makeup of the individual’s reproductive anatomy while gender refers to an 
individual’s lifestyle or personal identity.  Often these terms are used interchangeably. In this section we 
use sex to describe what is known about biological differences between males and females and gender to 
refer to what is known about behavior between men and women.   
 The literature on gender and health has discussed the detrimental impact of adherence to some 
traditional feminine gender roles on women’s health and wellbeing.18 These include gender-related 
expectations, such as societal standards for attractiveness; social norms regarding women’s caretaking 
role in relationships; and sanctions against anger expression by women. The messages women receive 
about gender-related expectations and the societal consequences of not measuring up to these 
expectations, can have health consequences.19  There are several common gender role concerns among 
women with IBS including; shame and bodily functions; bloating and physical appearance; and pleasing 
others, assertion and anger.19  
 One central theme that women with IBS commonly report is feelings of shame associated with 
losing control of bodily functions.  Women are taught that bodily functions are something to be kept 
private and secret. One important implication of such teachings is that bowel functioning becomes a 
source of shame and embarrassment more so than it does for men.  
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 The finding that women often score higher on indices of bloating  and constipation can also be 
discussed as a gender-related theme. Society’s focus on how women look (eg, thinness as a necessary 
standard of attractiveness)20 can lead women to experiencing bloating not only as a source of physical 
discomfort, but of psychological distress as well. The physical and psychological distress that women 
may experience with abdominal discomfort, coupled with the perception that their pain is being 
minimized or trivialized by health care professionals, may lead women to respond by becoming more 
hyper-vigilant to any sign of pain or discomfort.  
 Women as compared with men are socialized to please others, often at the expense of their own 
needs.  Women who express anger, make demands, or question authority are often given the label 
“hysteric,” have their complaints dismissed, or have their femininity called into question. Potential 
repercussions for women who express their own wants and needs are often sufficient to keep women 
silent. These social expectations of women can lead to the silencing of certain thoughts, feelings, and 
behaviors rather than jeopardize relationships that are in place.21 A study that compared women with  IBS 
patients with women with inflammatory bowel disease (IBD)  found women with IBS score higher on 
measures of self-silencing than IBD patients.21 In another, women reported shame in not living up to 
gender norm expectations for women in domains of relationships (taking care of others at the expense of 
their own needs), attractiveness (due to bloating) and lack of desire to engage in sex (due to IBS 
symptoms).22 Men in this study focused more on IBS symptoms impacting their paid employment and 
sense of control. They also found that in interactions with health care providers, women risked being 
trivialized and men risked being overlooked because IBS may be labeled as a women’s health concern. 
 
Gender and Social Factors 
It is important to acknowledge that health and illness occur within a larger social context. The meaning 
and expression of illness occur against a complex backdrop of a multitude of social determinants of 
health. The social determinants that have been investigated in FGIDs include: life stressors, history of 
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sexual, physical, and emotional abuse, early life experiences including gender role socialization, social 
support, and social factors as assessed by QoL scales.  
 There are limited studies to date that have assessed gender differences in life stress related to 
FGIDs.23 While the data support a significant role for life stress in IBS, future studies will need to 
determine whether there are differences in the relationship between stress and FGIDs in women and men.  
While stress affects the gut in most people, patients with IBS appear to experience greater reactivity to a 
variety of stressors.    
 One form of social stress that has received attention in the study of FGIDs is sexual, physical or 
emotional abuse.24  Table 1 shows the summary of studies fcused on gender differences in history of 
sexual, physical and emotional abuse.24-28  However, most work in this area has included only women or a 
women-predominate sample. Because of conflicts in the literature, more research is needed to determine 
whether there are gender differences in history of abuse in FGIDs.  
 Studies have also  investigated whether women and men with FGIDs differ on health-related QoL 
measures.29  For example, in a study of referral center and primary care patients, Simren et al30 found that 
women with IBS reported a lower QoL compared with men with IBS. Similar results were found in a 
Chinese outpatient population.29  Dancey et al31 found that men and women with IBS reported similar 
QoL scores as well as similar levels of symptom severity, perceived stigma, and illness intrusiveness. 
However, these authors also found gender differences in the relationship among these variables. For 
example, among women, IBS symptom severity exerted a significant impact on QoL, whilstfor men, the 
psychosocial impact of illness intrusiveness was greater in every domain except sexual relations. The 
authors suggest that these results have implications for how socialization shapes IBS-related gender 
differences. 
 
GENDER AND EPIDEMIOLOGY 
Most individuals with FGIDs do not seek healthcare and the decision to seek care introduces bias in 
research.  This section will focus on population-based research which is used to fully evaluate the 
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epidemiology and clinical symptoms in these individuals. The proposal that FGIDs may be more 
prevalent in women stems from a variety of sources reviewed elsewhere: studies documenting a greater 
prevalence of FGIDs with other chronic pain conditions which are more common in women 
(fibromyalgia, chronic pelvic pain), studies proposing an effect of the menstrual cycle on symptom 
severity and studies suggesting that particular agents are more effective in women.  
 
Functional Esophageal Disorders 
Functional esophageal disorders are common.32  Globus sensation and rumination syndrome are reported 
by about 1 in 10 of the population32-35 and are more common in women. Men with globus tend to have 
greater levels of somatization and depression.33 The prevalence estimates of functional chest pain, based 
on self-report, vary between 12.5 to 25%32, 36 with an equal gender prevalence in the general population.32 
There is a higher female-to-male ratio in tertiary care referral centers37 and women  tend to use terms like 
"burning" and "frightening" more than men.38 The challenge in research studies of functional esophageal 
disorders is identifying those individuals who predominantly have a functional esophageal disorder rather 
than gastroesophageal reflux disease, which is not associated with gender difference in rates or reflux 
symptoms.   
 
Functional Gastroduodenal Disorders 
Functional dyspepsia affects 15-20% of the general population39 and does not vary with gender.39-41  
Being a women was a significant predictor of functional dyspepsia when compared with organic causes of 
dyspepsia.42 Although females have physiological evidence of delayed gastric emptying there is little 
relationship between these measures and symptom severity or hormonal status.43, 44 Adolescent girls are 
twice as likely to report aerophagia as adolescent boys.45 The overall prevalence of functional vomiting is 
2.3% and there is no association with gender.46   
 
Functional Bowel Disorders 
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Female-to-male ratios of IBS vary widely geographically, from 3:1 in urbanized Western populations to 
1:1 in Nigeria47 (Figure 1 and Table 225, 29, 30, 32, 34-37, 39, 40, 45-75), but overall the prevalence of IBS 
internationally is 67% higher in women than in men (odds ratio 1.67 confidence interval 1.53-1.82).47   
 In terms of symptom severity, among patients with mild symptoms (< 3 Manning criteria), 65% 
were women, rising to 80% in those with more severe symptoms ( 3 criteria).25 Women have a more 
impaired QoL with IBS, with the somatic symptoms correlated to a gender-related increased prevalence 
of anxiety and depression. 25   
 There is a greater women to men predominance in non-pain associated symptoms of constipation, 
bloating, and extra-intestinal manifestations.48 Women are twice as likely as men to report bloating or 
abdominal distention.66, 67 Abdominal pain scores for men and women with IBS are similar; however, men 
report more diarrhea and women report more constipation.30, 48, 60, 65 In addition, women with IBS were 
more likely to report bloating and nausea as well as extra-intestinal symptoms compared to men.48 There 
is an amplification of GI symptoms during the late luteal and early menses phases.76  
 The female-to-male ratio for constipation is elevated for both the “outlet” (poor pelvic muscle 
tone) type and the combined “IBS+outlet” type of functional constipation 77. Women with functional 
constipation were two-times more likely to seek medical care compared to men.61, 62, 78  As with most 
FGIDs, the prevalence of functional constipation and IBS-constipation is lower in Asian populations, but 
the female preponderance is similar to Western populations.79  
 Functional abdominal pain is much more common in children and adolescents than adults, and 
the rate of diagnosis is higher in girls than boys.68 
 
Functional Disorders of the Biliary Tract and Pancreas 
The prevalence of sphincter of Oddi dyskinesia is 0.8%, being four to five times more common in 
women.32, 55 
  
Functional Anorectal Disorders  
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Prevalence rates of fecal incontinence vary from 2% to 11%,64, 70. Among nursing home residents, 
incontinence is more common in men,71 in contrast to older people living at home.69  There is no 
difference in gender in functional anorectal pain.32  Pelvic floor failure is common and increases with age, 
being more common in women.32   
 
GENDER AND OVERLAPPING FUNCTIONAL DISORDERS 
Patients with FGIDs often report other physical and mental comorbidities, ie, ‘extra-intestinal’ 
conditions.80  Co-morbid conditions reported by IBS patients include fibromyalgia, migraine headache, 
joint hypermobility syndrome, temporomandibular joint disorder, bladder pain syndrome/interstitial 
cystitis, anxiety and depression.81-83  All of these conditions have a female predominance in the general 
population and many have a pain component.  
 Among women with FGIDs a number of female specific conditions are more common when 
compared to non-FGID groups. These include dysmenorrhea, endometriosis, adenomyosis, leiomyomas,  
pelvic floor myalgia, vulvodynia, chronic cyclic pelvic pain, dyspareunia, dysmenorrhea, and polycystic 
ovary syndrome.  Dyspareunia and sexual functioning in women with IBS remain understudied problems.  
Hysterectomy is 3-fold higher in women with IBS84 suggesting that the overlap with gynecological 
conditions may contribute to greater health care seeking and subsequent surgical intervention. 
 Several mechanisms may account for the comorbidity in women with FGIDs, particularly IBS. 
These include brain activation patterns, dysregulation of the hypothalamic-pituitary-adrenal axis, immune 
dysfunction, visceral and somatic pain sensitivity alterations, autonomic nervous system dysregulation, 
and genetic susceptibility. Because the etiology and pathophysiology of each of these conditions are 
likely complex and multifactorial a single common pathogenesis has remained elusive.  Other factors, 
including access to health care and health care seeking behavior, may also contribute to gender 
differences in diagnosis of comorbid conditions.  The type, number, and duration of comorbid conditions 
may contribute to the toll of interpersonal stress.  
.  
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GENDER AND PATHOPHYSIOLOGY 
PRE-CLINICAL 
Visceral Pain Perception 
Under basal conditions, most studies have found that normal cycling females have a greater response than 
males to visceral pain stimuli.85, 86  Genetic background clearly has a role since the strain of rodent 
determines which sex is more sensitive to noxious visceral stimuli.87  Visceral pain can be enhanced by 
chemical irritation, inflammation, and stress. Generally all of these insults either show no sex difference  
or greater pain responses in female animals than males.85 Stress, particularly repeated stress and early life 
stress, also produces visceral hyperalgesia days or even months after the stress period, with female 
rodents being significantly more susceptible.88, 89   
 The role of sex hormones in visceral pain has received considerable attention and produced much 
controversy. Studying natural variations in sex hormones in female rodents is complicated by a much 
shorter (4-6 days) estrus cycle with smaller changes in the plasma estrogen and progesterone levels than 
in women.90 Since studies evaluating the effect of the estrus cycle in rodents have produced conflicting 
results,85, 91, 92 many investigators have resorted to ovariectomizing female rodents and comparing the 
effect of estrogen and progesterone replacement. This strategy too has resulted in conflicting observations 
that are probably due to the time between ovariectomy and pain testing, the dose of estrogen/progesterone 
and whether it’s administered abruptly with a single dose or at a slow constant rate.85, 93 The fact that 
estrogens can act rapidly by binding to estrogen receptors located in the plasma membrane, in addition to 
their slow effects mediated by gene expression94 may explain some of these differences.  
 
Somatic pain perception 
A great deal more preclinical work has been done on sex differences in somatic pain in animals with more 
equivocal results than visceral pain. Sex differences, if found at all, depend on the specific modality being 
tested (thermal, mechanical, chemical, electrical), the location or dermatome involved, and the 
experimental model (acute, neuropathic, ischemic, inflammatory pain).95  Again genetic background 
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seems to play an important role in determining which sex is more sensitive since different strains of mice 
and rats can produce opposite effects using the same pain test.95 The role of specific receptors and gene 
polymorphisms in sex-specific visceral and somatic pain responses is accumulating.86, 92  
 
Motility and Permeability  
Both estrogen and to a lesser extent progesterone affect GI motility and colonic permeability.92 Treatment 
of ovariectomized rats with the combination of estrogen and progesterone results in slower colonic 
transit,96 possibly mediated by effects on nitric oxide-containing neurons in the myenteric plexus97 and the 
number and function of mast cells in GI mucosa.98 In addition, stress has a greater effect on decreasing 
upper GI motility and increasing lower GI motility in female compared to male animals.99, 100 This effect 
is likely mediated by corticotropin-releasing factor receptor-1 which are potentiated by estrogen and 
expressed by colonic myenteric neurons.101 Estrogen also contributes to the maintenance of the intestinal 
barrier that serves an important role in the body’s defense against pathogens. The positive role of estrogen 
in maintaining intestinal barrier function may be through maintenance of tight junctions and/or influence 
on inflammatory response.102 
 
CLINICAL 
Abdominal Symptoms 
In the general population, women are more likely to report abdominal pain and pain-related IBS 
diagnostic symptoms (e.g. pain relieved by defecation),, while in the IBS population, the prevalence of 
pain-related symptoms does not vary by gender. In addition, IBS women report more constipation, 
straining, bloating, and abdominal distention, and men reporting more diarrhea-related symptoms, 
including increased stool frequency.103  
 
Visceral pain perception 
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There is no conclusive data to suggest gender influences visceral pain perception or the referral of pain to 
GI stimulation in healthy and FGID subjects.104-108 Women, however, are more likely to exhibit increased 
sensitivity following repetitive sigmoid distention than men with IBS.107, 109  Reasons for inconsistencies 
across studies may include study design, small subject numbers and techniques, ovarian hormone and 
receptor levels, and/or stress levels, mood, vigilance,  and early-life and social factors.  
 
Somatic pain perception 
Studies suggest that healthy women tend to exhibit greater somatic pain sensitivity than men.86 In FGIDs, 
studies are scarce with only one study in IBS suggesting that thermal sensitivity does not differ between 
sexes.110 Variability between studies is probably for similar reasons discussed for visceral pain perception.  
  
Motility 
Esophageal anatomy and innervation do not appear to differ significantly by gender, and only minor 
gender-specific differences have been reported in esophageal motor function.111 Slower gastric emptying 
rates of both solids and liquids have been shown in females compared to males.112-116 Postprandial 
proximal gastric relaxation was prolonged and perception scores increased in women compared with 
men.117 Studies have found colon transit times to be shorter in men than women, particularly in the right 
colon.118-120 Rao et al, using ambulatory 24-hour colonic manometry, found pressure activity in the colon 
of healthy women to be reduced compared with age-matched men.121 Phase of menstrual cycle was not 
controlled in these studies. There are no published non-drug studies comparing colonic motility in women 
and men with IBS. Anal sphincter pressures, anal pressures during maximum sphincter contraction, and 
volumes required to induce a desire to defecate have been reported to be lower in women.122, 123 
 
 
 
Cardioautonomic Tone 
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Autonomic nervous system (ANS) dysfunction has been reported in patients with IBS.124 However, few 
studies have evaluated gender differences in measures of autonomic function other than GI motility in 
persons withIBS. Cheng and coworkers reported significant blunting of the ANS response to flexible 
sigmoidoscopy (a visceral stressor) in IBS compared with controls, and that overall women had higher 
cardiovagal tone and lower cardiosympathetic balance compared to men.125 
 
Central Processing of Visceral Stimuli  
Healthy subjects:  Using functional magnetic resonance imaging (fMRI), Kern et al126  demonstated  
greater  response to rectal distension in sensory and affective regions (dorsal anterior cingulate cortex, 
prefrontal cortex and insula cortex) in females compared with males.  In contrast, Berman et al127 found a 
trend for greater activation of the insula, and anterior and midcingulate cortex to rectal distension in men 
compared with women. A more recent fMRI study reported greater activity in the dorsolateral prefrontal 
cortex and middle temporal gyrus during anticipation of rectal pain, and in the cerebellum and medial 
frontal gyrus during painful rectal stimulation in  women compared with men.128  Although a study using 
magnetoencephalography while recording cortical evoked potential to painful esophageal stimulation 
reported no sex difference,129 sex differences in brain response to esophageal pain have been observed.130  
Despite no significant differences in psychophysiological factors known to influence brain processing, 
such as anxiety, personality type, autonomic response to pain, and pain perception levels and thresholds,  
women compared to men exhibited a greater decrease in  amygdala activity during anticipation of 
esophageal pain and a greater increase in  midcingulate cortex and anterior insula activity during 
esophageal pain.130  These observations were interpreted as women having greater engagement of 
cognitive coping strategies to the anticipation of visceral pain, and greater emotional response during 
actual esophageal pain.129  
FGID subjects: Initial brain imaging studies using rectal balloon distension in IBS patients found that  
male patients exhibited greater activation compared to female patients of the insula,131, 132  as well as 
dorsolateral prefrontal cortex and dorsal pons/periaqueductal gray.132  In contrast, female IBS patients 
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demonstrated greater activation of the ventromedial prefrontal cortex, right anterior cingulate cortex, and 
left amygdala compared with male patients.132  These data suggest female patients have greater activation 
of affective and autonomic regions, while males show a greater activation of regions in corticolimbic pain 
inhibition system.  A follow-up study using connectivity modeling of the same data suggested that the 
differences between men and women are mainly due to differences in the effective connectivity of 
emotional arousal circuitry rather than visceral afferent processing circuitry (Figure 2).133   
More recent neuroimaging studies have demonstrated brain activity/connectivity differences 
between men and women, even in the absence of a noxious stimulus (eg, rectal distension).  Female IBS 
patients have shown higher frequency power of the insula compared with male patients.134  Although sex 
differences were seen in healthy controls in the resting state, oscillatory dynamics of emotional arousal 
regions  (amygdala and hippocampus) were exaggerated in IBS patients, mainly due to an increased high 
frequency power in female patients.134  Furthermore, sex differences in the resting state oscillatory 
dynamics of sensorimotor regions seen in healthy subjects (greater low frequency power in men) were 
reversed in IBS patients with greater low frequency power in women.134 A second resting state study 
demonstrated sex differences in the functional connectivity between the dorsal anterior insula (INS) and 
medial pre-frontal cortex (PFC) and precuneus in IBS are similar to healthy subjects, but more 
enhanced.135 These findings may relate to females dedicating more resource allocation to interoceptive 
awareness, while males rely more on cognitive processes with IBS placing further stress on this bias.  
Finally, sex difference in the impact of early adverse life events (EALs) on resting state brain connectivity 
has been demonstrated in IBS patients.136  EAL scores were associated with greater connectivity of 
thalamus, insula, anterior cingulate cortex, and middle temoral gyrus with the cerebellar network in men 
only.  The cerebellar network is involved in fear perception, motor function, and visual-motor learning, as 
well as physical and psychological pain.  The functional consequences of these sex-specific alterations in 
cerebellar network alterations remain unknown. 
Sex differences in structural changes of the brain in IBS have also been demonstrated. Female 
patients have demonstrated significantly less cortical thickness in the right subgenual anterior cingulated 
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cortex than male patients.137  Moreover, using diffusion tensor imaging, reduced integrity of sensorimotor 
and descending pain modulation pathways has been demonstrated in female compared with male IBS 
patients.  Such differences were not seen in healthy subjects.138   
 
Genetics and Immunologic/Microbiome 
 Multiple factors including genetics, the environment, sex hormones and the gut microbiota may 
modulate the immunologic response to inflammation and infection.88 Our understanding of the role of 
inflammatory factors in FGIDs and genetics especially IBS is rapidly increasing. The use of new ‘omics’ 
approaches will need to consider sex as a potential factor in terms of understanding new metabolomics 
and transcrioptomics findings. Further research is needed to clarify the potential relevance of these factors 
in immune system dysregulation and FGIDs. 
 Emerging evidence suggests that interactions between gut microbiota and altered immune 
function may play a role in the pathogenesis of IBS , and several studies support the importance for 
immune activation in the pathophysiology of post-infectious IBS.139 Female gender in both adults and 
children has been reported as a risk factor for developing IBS symptoms following infectious 
gastroenteritis.140, 141 The gut bacteria are modulated by sex steroid hormones, in particular estrogen.  In 
addition, gut bacteria can influence the metabolism of estrogen (Figure 3).142 Flack and colleagues first 
proposed the concept of ‘microgenderome’, the bidirectional interaction between sex hormones and the 
microbiota.143  
 
GENDER AND TREATMENT RESPONSE 
Clinical Assessment  
The clinical implications of gender are relevant in both the diagnosis and clinical management of FGIDs. 
Beginning with the history, IBS-like symptoms are often present in gynecological conditions, the most 
serious of which are ovarian and endometrial cancer and should be included in the initial differential 
diagnosis.  Asking the patient when symptoms started may provide important information about etiology 
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and subsequent approaches to management.  There are history and examination features unique to 
women: menstrual history, gynecological surgery, bimanual pelvic examination. The comorbidity of IBS 
with gynecological pain conditions and pelvic floor dysfunction warrants careful examination. In the 
differential diagnosis, clinicians should avoid mistakenly employing the gender-prevalence to influence a 
premature diagnosis of a FGID.  
 
Psychological Treatment 
Whether gender makes a difference to outcomes with psychological therapy is unclear since women 
outnumber men in most FGID treatment trials.144 These trials have not been sufficiently powered or 
included sub-analyses to determine whether or not there is a differential response to treatment between 
genders.145, 146   
 There is no gender bias in outcomes with cognitive behavioral therapy, psychological therapy or 
emotional awareness training for IBS,147 and gender was not selected into a predictive model of treatment 
response. By contrast, Guthrie and colleagues148 reported minor advantages for women in response to 
therapy compared to men, but gender was not selected into their final analysis model. For individual 
psychotherapy in patients with functional dyspepsia and severe IBS,149 efficacy is similar to selective 
serotonin reuptake inhibitor therapy with no gender difference in outcome with either treatment.   
 Two evaluations of hypnotherapy150, 151 gave contrasting results with respect to gender. An audit 
of 1,000 IBS patients who met Rome II criteria (80% female) for IBS and underwent hypnotherapy for 3 
months found that 80% of women improved compared to 62% of men.151 A study of 250 participants 
noted a poor response in men with IBS with diarrhea.150 By contrast, a randomized controlled trial,151 
albeit in a smaller population, demonstrated that gender, age, disease duration, and IBS type had no 
influence on the long-term success of hypnotherapy.   
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Pharmacologic Treatment  
Psychotropic Agents. A recent systematic review of antidepressant therapy identified that most studies 
did not conduct separate analyses by gender.146  
   
Gut-Directed Agents. A number of small, variable quality studies have been subject to meta-analysis152 
and shown modest benefits over placebo for fiber, anticholinergics, and peppermint oil, but no separate 
analysis of gender difference was undertaken.  
 Therapies targeted at serotonin (5-HT) receptors in the gut seem to have a differential effect in 
men and women. Alosetron, a 5-HT3 antagonist, providing 26-40% adequate relief of pain response rate 
in women, gives 33% pain decrease in men at the same dose.153 The basis for this gender difference is not 
clearly established.  Alosetron is more effective in slowing colonic transit,154 attenuating the gastro-
colonic response, and increasing rectal compliance155 in women than men.    
 Three large series156 of prucalopride, a highly selective 5HT4-agonist, recruited 85% female 
patients and demonstrated equal efficacy in both sexes. For other drugs commonly used to treat motility 
disturbance (domperidone, opioid-based constipating agents, laxatives, probiotics), there is no evidence of 
a gender-related difference in efficacy.157    
 Most medications for FGIDs are cleared through the cytochrome P450 pathway that can be 
affected by female sex hormones. While women clear drugs more quickly than men through this pathway, 
this is balanced by the difference in body size and adiposity of women. There have been no clinically 
significant differences in the pharmacokinetics of FGID drugs, and hence, dosages need not be adapted by 
gender. 
 
LIFE STAGES AND AGING 
The FGIDs affect people across the spectrum of age. Some FGIDs increase with age while others 
decrease. Some begin in childhood while others start after developmental stages including puberty and 
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menopause. The trajectory of many FGIDs are unknown due to lack of long term follow up.  Cohort 
studies with pre-identified clinical and biological markers may yield important information about the 
normal GI tract aging in concert with the evolution and progression of FGIDs. 
 Extensive epidemiological data exist for IBS, dyspepsia, heartburn, constipation, and fecal 
incontinence, but less is known about the other FGIDs. The presence of FGIDs in children is well 
recognized. The exact age of onset of FGIDs remains to be determined. A link between childhood IBS 
and adult IBS remains to be established.   
 Both laboratory animal and human data indicate that EALs may contribute to either increased 
visceral sensitivity later in life and/or potentially visceral and somatic conditions.24  While EALs results 
in higher rates of IBS in both genders, women appear to be more susceptible to the development of 
pathologies following exposure to EALs.89   
 Approximately 70-95% of women report heartburn, nausea or vomiting during their pregnancies.  
Most episodes of heartburn occur during the first and second trimester.   
 The perimenopause is defined as the period of transition to menopause.  In a cross-sectional study 
of premenopausal and postmenopausal women with IBS, there were more GI symptoms in early post-
menopausal women compared to premenopausal women.158 Menopause is the cessation of a woman’s 
reproductive ability.  Understanding the effects of menopause on FGIDs is confounded by the effects of 
aging, the presence of co-morbid conditions, and medication use (ie, hormone replacement use (HRT)).  
In one study using the General Practice Research Database in the UK, investigators found that current and 
past users of HRT had an increased risk (incidence 1.7 in non-users and 3.8 among users) of IBS 
compared to non-users.159 
 Overall the prevalence of IBS decreases with age in both men and women.160  The existing 
literature is discordant with regard to the changes in the estimates of bloating by age.32 Most studies find 
that the prevalence of constipation increases with advancing age,63, 64, 161 Less is known regarding 
functional diarrhea, although one study identified decreasing rates of diarrhea with age.46   
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 There is some evidence to suggest that with aging there is reduced biodiversity. However, it is 
difficult to separate out changes that are related to aging, per se, or lifestyle, history of antibiotic 
treatment, hospitalization, and frailty.  Reductions in fiber intake due to poor dentition, decreased saliva 
production, reduced economical resources may also contribute to age-related changes in microbiota 
composition.  
 Fecal incontinence has been extensively studied and increases with age. Data from the Nurse’s 
Health Study show that 4% of women age 62 to 87 have fecal incontinence and 7% have both urinary and 
bowel incontinence.162   
 
METHODOLOGICAL ISSUES IN FGIDS 
As a result of methodological issues limiting interpretation of studies, there remain many unanswered 
questions concerning gender, age, and patient’s perspective in FGIDs. Due to the female predominance 
and greater likelihood of women to participate in research studies, there are insufficient numbers of male 
participants to make meaningful interpretations and adequately assess gender and sex differences in 
psychological, physiological, and treatment studies. Given the intersection of gender and socioeconomic 
factors in women’s health the environment, relationships, and resources (eg, socioeconomic status) need 
to be considered when assessing gender differences. Another major methodological concern is that most 
studies use a cross-sectional design which limits the more comprehensive understanding of the 
pathogenesis, development, course and impact of these disorders in men and women.  
 Many physiologic studies utilize relatively small sample sizes and do not account for 
psychosocial variables, overlapping FGID or co-morbidities, abuse history or EALs, and therefore, may 
not apply to the general patient population. These studies may be influenced by the selection bias of 
participants who are willing to undergo invasive research protocols.  
 Translating the various mechanisms of pain and GI function from animal studies to humans is 
challenging. Differences in the type and strain of the animal model and type of stressor, if used, need to 
be taken in account when interpreting these studies. 
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 Similarly for women, the menstrual cycle needs to be considered in studies. In most studies, 
menstrual phase is frequently not determined, or is assessed by the count forward/backward method and 
not by measuring the luteinizing hormone surge or ovarian hormone levels to more accurately assess the 
follicular and luteal phases. Other confounding methodological issues include the use of oral 
contraceptive agents, HRT and pre vs. postmenopausal status in women. The impact of the transition from 
a premenopausal to perimenopausal state to menopause remains unknown. 
 Most studies examining psychological factors have focused on anxiety and depression and, to a 
lesser extent, personality traits. Other aspects of psychological functioning such as quality of 
relationships, social support, health perceptions, traumatic and stressful events, and effects of childhood 
experience other than abuse have been largely ignored in studies comparing men and women.  
 Adequate sample sizes of each gender, particularly men, and comparable treatment doses must be 
obtained to determine if men and women respond similarly to treatment. There may be gender bias in the 
placebo response. Patients for clinical trials are generally recruited from specialty practices where women 
are more likely to be referred than men, thus compounding problems of selection bias.  
 Future studies will need to have adequate numbers of men with gender-related variables such as 
history of EALs, abuse, anxiety, or depression.19 At the same time, greater attention needs to be given to 
transgender men and women.  
 In summary, this review emphasizes: (1) the importance of the patient’s experience and 
perspective, (2) the influence of society, culture, gender, and age on all aspect of the individual’s 
experience, (3) the influential role of an individual’s sex on the biologic and physiologic processes of 
brain-gut interactions, and (4) the potential of the health care provider in influencing patient outcomes.  
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FIGURE LEGEND 
Figure 1. Odds ratio for irritable bowel syndrome (IBS) in women vs. men according to 
geographical location. Data are grouped according to the geographic region. Numerically higher ratios 
are reported from the Western world.48 
Figure 2. Estimated effective conductivity differnces between men and women in proposed network 
comprising the “homeostatic-afferent”, “emotional-arousal”, and “cortical-modulatory circuits”. The 
operation of the proposed network (as estimated by the completely unconstrained model) during Baseline, 
Inflation, and Expectation (columns) is presented for females (top rows) and males (bottom rows). The 
beta coefficients (effective connectivity) are depicted by the thickness and color of the arrows. Solid 
arrows represent a parameter estimate that was considered significantly different from zero whereas 
dashed lines represent nonsignificant coefficients. Panel A depicts positive coupling whereas Panel B 
represents negative coupling. Amyg: Amygdala; iACC: infragenual cingulate cortex; INS: insula; LCC: 
locus coeruleus complex; mOFC: medial orbital frontal cortex; sACC: supragenual anterior cingulate 
cortex.  
Figure 3.  Sex hormones in the mutual brain-gut-microbiota interactions. Sex hormones influence 
peripheral and central regulatory mechanisms involved in the pathophysiology of IBS contributing to the 
alterations in stress response, visceral sensitivity and motility, intestinal barrier function, and immune 
activation of intestinal mucosa. Sex hormones have also a direct effect on the gut microbiota.  ENS: 
Enteric nervous system. 
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TABLES 
Table 1. Gender Differences of History of Sexual, Physical and Emotional Abuse in Persons with and 
without IBS  
Author 
(Year) 
Early life events Findings Gender differences 
within group 
comparisons 
25 
 
Childhood abuse,  
Sexual abuse 
A history of sexual abuse was more 
common in women than in men but 
the authors did not differentiate 
between patients with or without IBS.  
Not addressed 
26 
 
Severe lifetime sexual 
trauma, severe childhood 
sexual abuse, lifetime sexual 
victimization 
All of the IBS patients studied that 
reported a history of sexual abuse 
were female. 
Women > men 
24 
 
General trauma, physical 
punishment, emotional 
abuse, and sexual events  
Significant differences were observed 
mainly in women with IBS. Various 
types of early adverse life events are 
associated with the development of 
IBS-particularly among women.  
Women > men 
27  Childhood abuse No significant association of 
childhood adversity with the 
likelihood of developing IBS in either 
men or women. 
No differences 
28 Childhood abuse A history of child abuse was similar in 
case and control group. But the 
authors did not differentiate between 
patients with or without IBS.  
Not addressed 
IBS: irritable bowel syndrome 
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Table 2.  The Effect of Sex and Age on the Prevalence of FGID 
FGID Effect of sex References 
for sex 
Change 
with age 
References 
for age 
Esophageal 
 Globus 
 
F>M 
 
32 
49 
 
 
32 49 
 
 Rumination 
 
F=M 32  
32 
 F>M 34 
35 
 Functional chest pain 
  
F=M 49 
36 
50 
 
32 49 
 
F>M(at tertiary care) 
 
37 
 Functional heartburn F=M 49 
51 
= 32 
    Dysphagia F>M 32 
49 
 32 
Gastroduodenal 
 Dyspepsia F=M 32 
39 
40 
 52 
46 
53 
 Aerophagia M>F 32 
 
 32 
 
F > M 54 
45 
 42 
 Functional vomiting F=M  
46 
  
46 
Biliary tract F > M 32 
55 
 32 
Lower GI tract 
 IBS F > M 56 
32 
25 
47 
29 
57 
 
 
32 
58 
59 
 
 Functional constipation F>M 56 
32 
 46 
60 
30 
61 
62 
 63 
 
64 
 Functional diarrhea 
 
M>F 
 
32 
46 
60 
 
30 
48 
65 
 
 
46 
 Functional bloating Discordant 32 Discordant 32 
 43 
F>M  
66 
67 
48 
 
    FAPS F>M 32 
68 
 32 
 Fecal incontinence 
 
F>M(at home) 69   
70 
64 
M>F 
(nursing homes) 
71 
 Functional anorectal pain F>M 32  32 
 Outlet delay F > M 72 
73 
74 
75 
= 72 
FAPS: functional abdominal pain syndrome; FGID: functional gastrointestinal disorders; GI: 
gastrointestinal; IBS: irritable bowel syndrome. 
